Investigational drug · Phase 2
KH617
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Recurrent Glioblastoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "KH617"
First trial start
2025
Aug 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KH617", any sponsor or status.
Conditions studied
As listed on its trial records.
- Recurrent Glioblastoma
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "KH617" as an intervention, largest first.
- Phase 2 Clinical Trial of KH617Not yet recruiting
Sichuan Honghe Biotechnology Co., Ltd.Industry
NCT07138001 · 60 participants (planned) · Start Aug 2025 · Primary completion Sep 2027
Drug: KH617; TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16 · For: Recurrent Glioblastoma
- Phase 1 Trial of KH617Recruiting
Sichuan Honghe Biotechnology Co., Ltd.Industry
NCT05667194 · 45 participants (planned) · Start Dec 26, 2022 · Primary completion Sep 2030
Drug: KH617 · For: Advanced Solid Tumors
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Recurrent Glioblastoma
- TGX-007Phase 21 trial
Trogenix ltd · Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma
- ValaciclovirPhase 21 trial
Trogenix ltd · Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma
- VP-16Phase 21 trial
Sichuan Honghe Biotechnology Co., Ltd. · Recurrent Glioblastoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.